Gregory Renza
Stock Analyst at RBC Capital
(1.16)
# 3,307
Out of 4,810 analysts
207
Total ratings
26.2%
Success rate
-14.52%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Outperform | $16 → $15 | $2.05 | +631.71% | 6 | Mar 27, 2025 | |
| CRMD CorMedix | Reiterates: Outperform | $12 | $7.13 | +68.30% | 6 | Mar 26, 2025 | |
| VSTM Verastem | Maintains: Outperform | $16 → $14 | $4.78 | +192.89% | 10 | Mar 21, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Sector Perform | $6 → $5 | $1.77 | +182.49% | 10 | Mar 19, 2025 | |
| EXEL Exelixis | Maintains: Outperform | $38 → $40 | $35.74 | +11.92% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $179 → $178 | $101.75 | +74.94% | 13 | Feb 26, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $26 → $27 | $9.85 | +174.11% | 11 | Jan 29, 2025 | |
| AMGN Amgen | Reiterates: Outperform | $324 | $293.92 | +10.23% | 16 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $61 | $17.11 | +256.52% | 12 | Jan 15, 2025 | |
| PCRX Pacira BioSciences | Reiterates: Sector Perform | $18 | $24.97 | -27.91% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $4.20 | +1,042.86% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.02 | +395.05% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $4.63 | +115.98% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $13.30 | +253.38% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $18.74 | +81.43% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 → $1.5 | $0.31 | +377.10% | 13 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $27.52 | +107.12% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $66 | $20.06 | +229.01% | 2 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $2.92 | +36.99% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.55 | +261.73% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $35 | $7.07 | +395.05% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $8.94 | +280.31% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.01 | +431.56% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $26 | $14.86 | +74.97% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.21 | +561.16% | 11 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $5.38 | +3,245.72% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.58 | +4,963.29% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.13 | +2,554.87% | 3 | Jun 2, 2020 |
Perspective Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $2.05
Upside: +631.71%
CorMedix
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $7.13
Upside: +68.30%
Verastem
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $4.78
Upside: +192.89%
Inovio Pharmaceuticals
Mar 19, 2025
Maintains: Sector Perform
Price Target: $6 → $5
Current: $1.77
Upside: +182.49%
Exelixis
Mar 13, 2025
Maintains: Outperform
Price Target: $38 → $40
Current: $35.74
Upside: +11.92%
Jazz Pharmaceuticals
Feb 26, 2025
Maintains: Outperform
Price Target: $179 → $178
Current: $101.75
Upside: +74.94%
Nurix Therapeutics
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.85
Upside: +174.11%
Amgen
Jan 24, 2025
Reiterates: Outperform
Price Target: $324
Current: $293.92
Upside: +10.23%
IDEAYA Biosciences
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $17.11
Upside: +256.52%
Pacira BioSciences
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $24.97
Upside: -27.91%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $4.20
Upside: +1,042.86%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.02
Upside: +395.05%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $4.63
Upside: +115.98%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $13.30
Upside: +253.38%
Dec 13, 2024
Initiates: Outperform
Price Target: $34
Current: $18.74
Upside: +81.43%
Dec 11, 2024
Reiterates: Sector Perform
Price Target: $2 → $1.5
Current: $0.31
Upside: +377.10%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $27.52
Upside: +107.12%
Dec 6, 2024
Reiterates: Outperform
Price Target: $66
Current: $20.06
Upside: +229.01%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $2.92
Upside: +36.99%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.55
Upside: +261.73%
Nov 1, 2024
Reiterates: Outperform
Price Target: $35
Current: $7.07
Upside: +395.05%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $8.94
Upside: +280.31%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.01
Upside: +431.56%
Aug 7, 2024
Maintains: Outperform
Price Target: $29 → $26
Current: $14.86
Upside: +74.97%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.21
Upside: +561.16%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $5.38
Upside: +3,245.72%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.58
Upside: +4,963.29%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.13
Upside: +2,554.87%